Categories
October Surprise 2024

Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with acquired MET …

Conclusions: Vebreltinib and PLB1004 at RP2D demonstrates notable efficacy and manageable safety in EGFR-mutated NSCLC with METamp or METov after EGFR-TKIs failure.